Background Clinical outcome assessments may not fully capture patients' perspectives of treatment benefit or tolerability. Incorporating individual exit interviews might enhance the description of the patient experience of drug effects. Objective The objective of this study was to evaluate the patient treatment experience in a clinical trial of treatment-resistant depression utilizing exit interview methodology. Methods Individual patient interviews were conducted with subjects exiting two phase II clinical trials involving investigational agents for treatment-resistant depression. Interviews included standardized questions about patients' perceptions of health changes and interest in continued use of the investigational agent. Constant comparative analysis of blinded data was used to identify, code, and categorize the data followed by a subsequent analysis of unblinded data to evaluate any potential treatment differences.
Introduction
Clinical outcome assessments (COAs) comprise four different assessment types, including clinician-, patient-, and observer-reported outcomes and performance outcome measures. Clinical outcome assessments are frequently included in clinical trials to assess how patients feel and function relative to a disease, condition, or treatment [1] . Patient-reported outcomes (PROs) provide this insight directly from the patient's viewpoint without the influence of other individuals and typically provide a unique perspective on an outcome that may otherwise be unobtainable [2] . Such data may provide important context in regard to the patient
Key Points for Decision Makers
While clinical outcome assessments are typically relied upon in support of the overall strategy for a given drug development program, traditional assessment tools may not entirely capture the patients' experiences and perspectives regarding treatment effects.
The addition of individual interviews may provide a deeper appreciation of the overall treatment experience from the patient perspective, providing researchers with a previously untapped resource to both understand concepts that are relevant and important to patients and more fully interpret the results obtained via traditional assessment tools.
Inclusion of a standardized exit interview provided insight into the patient-perceived treatment experience in early-phase studies 2001 and 2002, thereby informing the development plan for esketamine.
understanding into determining issues in regard to protocol adherence, attrition rates, and underlying factors that could result in the dilution of differences between treatment arms [4, 5] .
In general, PRO measures included in clinical trial protocols address the concepts that are anticipated to be relevant and important to patients at the outset of a study. Incorporation of exit interviews may provide an opportunity to capture important patient-perceived effects that may have otherwise been missed. This can be helpful in early development trials to inform COA measures for integration into later phase development, particularly when a treatment with a new mechanism of action is under investigation and where potential treatment effects are not fully understood. Additionally, limitations of the selected outcomes may not be well characterized and become apparent only after widespread clinical use [3, 6] .
Through the use of exit interview data, clinical trial sponsors, qualitative researchers, and other stakeholders may enhance characterization of unmet medical needs via direct patient descriptors. The richness of this type of data may also provide support for future measurement strategies and the demonstration of product effects from a patient perspective. Inclusion of exit interviews as a means of more fully exploring the patient experience is increasingly becoming more commonplace within the drug development landscape.
To address the research goals for this study, a standardized semi-structured exit interview, developed previously by Janssen and RTI Health Solutions, was incorporated. The interview questions were designed to allow for more robust patient input in the early phases of drug development to further elucidate research insights not otherwise captured. Development of the instrument used for the exit interviews included direct patient input across an initial two iterative rounds of testing with 22 adult subjects taking either a new medication for type 2 diabetes or any new prescription medication. This initial research was undertaken to explore both the content validity and feasibility of administering the interview to participants within the context of a clinical trial and served as the basis for evaluation of a core set of interview questions. Disease-specific questions were then developed based on input from patients across multiple populations of interest including additional patients with type 2 diabetes, obesity, and major depressive disorder to allow appropriate expansion of the interview on a trial-specific basis. The modified version of the interview questions was further evaluated across two subsequent iterative rounds of interviews with 12 individuals who had received a physician diagnosis of major depressive disorder and had obtained a new or additional prescription medication for the treatment of depression in the previous 6 months. Interviews focused on evaluation of the comprehensibility and content validity experience including assessment of the clinical meaningfulness of change to clinical indices and measures. While COAs are often integral to the overall strategy for a given drug development program, traditional assessment tools may not fully capture the patients' experiences and perspectives regarding treatment effects [3] . Researchers may find a rich, otherwise untapped data source by incorporating individual interviews into a clinical trial as a robust means of fully capturing the patient voice to further enhance the representation of the patient experience.
Interviews that occur within a clinical trial setting at the end of treatment or at the last study visit are commonly known as exit interviews [3] . Typically, an exit interview is a discussion with a subject that follows a semi-structured script that includes prespecified concepts for exploration but allows for flexibility and a more in-depth discussion of experiences than structured COA instruments. Further, rigorous analysis of exit interview data will follow a prescribed methodological approach. Exit interviews can complement COAs and provide a unique opportunity to collect qualitative data from the target patient population who have experience with the investigational treatment and have completed other COA measures in the context of a clinical trial. These types of interviews are applicable throughout the drug development process for a variety of reasons. Specifically, exit interviews may supplement and assist the interpretation of clinical trial data and facilitate the development of optimal measurement strategies for future studies. Moreover, exit interviews may reveal positive and negative treatment impacts not otherwise captured by structured COA endpoints as well as provide an of the interview questions within a major depressive disorder population.
This study sought to explore the value of exit interviews, and the data generated using this approach, by employing exit interviews in two phase II clinical trials of esketamine/ ketamine [7, 8] . Specifically, results from the interviews were used to identify key concepts of importance to patients in relationship to treatment effects and further supported insights into the appropriate selection of endpoints in later stage clinical trials.
Methods
Two phase II trials with patients diagnosed with treatmentresistant depression were conducted [7, 8] . One trial (2001) [7] included intravenous (IV) esketamine, the other (2002) [8] included IV ketamine (henceforth referenced as "esketamine/ketamine" when discussed together). Further trial-specific detail is included below. Before any participant contact, both studies were reviewed and approved by an institutional review board and all procedures were in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments. Written informed consent was obtained from all participants prior to recruitment.
To fully evaluate treatment impacts of esketamine/ketamine, a standardized semi-structured exit interview was included in both studies. The goal of the interview was to capture early signal detection data (including both positive and negative signals of esketamine/ketamine) and thereby more fully assess the patient treatment experience in the clinical trial.
Exit interviews were conducted at the end of the doubleblind treatment or early termination for subjects participating in both phase II clinical trials. Site staff were trained by the sponsor on interview conduct methodology and data collection procedures. An independent quality review of recorded interviews was conducted and interim feedback provided to the sponsor. Retraining was conducted as needed to help improve overall interview quality.
Clinical Trials
Trial 2001 (NCT01640080) was a double-blind, doublerandomization, placebo-controlled study evaluating IV esketamine for treatment-resistant depression (n = 30 overall) [7] . Eight investigative sites in three countries (Belgium, Germany, and Poland) enrolled subjects in the trial. Subjects were randomized on day 1 into one of three treatment groups: a low dose, a high dose, and placebo. Subjects with a reduction in the Montgomery-Åsberg Depression Rating Scale total score of > 50% vs. baseline on days 2, 3, or 4 (prior to dosing) were considered responders [9] . The second dose of study medication was determined based on whether subjects met the response criteria. Exit interviews were conducted on study day 7, the last day of the double-blind treatment phase, on a total of 29 subjects. Figure 1a presents the study design [7] .
Trial 2002 (NCT01627782) was a double-blind, randomized, placebo-controlled, parallel-group, dose-frequency study of IV ketamine, an investigational IV agent for treatment-resistant depression (n = 68 overall) [8] . Fourteen investigative sites in the USA enrolled subjects in the trial. Subjects were randomized on day 1 of the double-blind treatment phase into one of four treatment groups: the investigational agent two times weekly, the investigational agent three times weekly, placebo two times weekly, and placebo three times weekly. Exit interviews were conducted on a total of 61 subjects: 27 subjects on study day 29 (the last day of the double-blind treatment phase), 32 subjects at an early termination visit, and two subjects as part of an unscheduled visit. Figure 1b presents the study design [8] .
Interview Methods and Data Collection
Site staff were thoroughly trained on the use of the interview materials and of best-practice interview techniques and procedures to ensure that any adverse events noted during the interview were appropriately reported as study adverse events. Only trained site staff conducted the exit interviews for both trials. The interviews included eight standardized questions about subjects' perceived health changes during treatment; the impact (i.e., positive effect, negative effect, or no effect), importance of the change (not at all important, slightly important, moderately important, very important, extremely important), onset of those changes; and subjects' willingness to continue the study medication. Pre-scripted probes were also included in the interview to enable interviewers to consistently elaborate on the interview questions in response to patient feedback, as needed. The data collection worksheet was used to facilitate note taking and standardize data collection during the interview process. The site staff compiled a list of any verbatim health changes reported by the patient at the beginning of the interview. Each health change was documented as described in the patient's own words, and subsequently the interview covered detailed information about each health change. For Trial 2001, exit interview and data collection worksheets were translated from US English and interviews were conducted in the local language. The translation process included two forward translations into each targeted local language, reconciliation, and two back translations into English, followed by final reconciliation. Data were collected via an electronic case report form, which was recorded in English, and the interviews were not audio recorded. For Trial 2002, interviews were recorded, audio files were used to create interview transcripts, and hand-written copies of available data collection worksheets were collected and compared with the electronic case report form data.
Analytic Methods
The interview data, and information collected on data collection worksheets for both trials were analyzed to identify and summarize the benefits or impacts during treatment as reported by subjects during the interview process. The question asking about health changes was designed to allow for verbatim response of any changes noticed by the patient. A pre-scripted list of health changes for an individual to select from was not used. In addition to the data collection worksheet, typed transcriptions of the audio recordings were used for Trial 2002 (available for 58 of the 61 interviews conducted) in the qualitative analyses. To ensure consistency, all coding and analysis were conducted by the same two RTI Health Solutions staff with a combined 40 years of experience conducting qualitative research. A standard qualitative analysis method known as constant comparative analysis was employed to identify, code, and categorize patterns or themes found in the data [10] . Constant comparative analysis allows the researcher to confirm that an accurate reflection of each participant's views has been captured. These analyses initially were conducted in a blinded manner, such that each subject's treatment group was not evident to the analysts. Additional unblinded qualitative reviews were then conducted by treatment group for each trial to determine whether any themes by treatment group emerged among the identified health changes reported.
For Trial 2002, a subsequent qualitative analysis was conducted for subjects receiving active treatment to determine whether "clusters" or patterns existed among the identified health changes reported by subjects. An analysis of the data was conducted wherein subjects reporting at least one of the health changes identified as a dominant or prevailing theme, based upon the number of participants that reported the health change, were included. All health changes reported by these subjects were hand coded, reviewed, and crosscompared among all others included within the analysis sample to identify any emerging themes among the health changes reported. No formal statistical evaluations were conducted. Because the sample size was small, to identify any meaningful patterns, data from the ketamine treatment groups were combined. This analysis was conducted to better understand the study population and attempted to identify any meaningful patterns related to treatment effects specific to the impact across multiple areas of treatment-resistant depression to patients. Table 1 presents the characteristics of the trial subjects who participated in exit interviews. For the Trial 2001 analysis sample of exit interview participants (n = 29), all subjects were white and ranged in age from 20 to 62 years, with a mean age of 42.6 years. Approximately two-thirds of the analysis sample was female. For the Trial 2002 analysis sample of exit interview participants (n = 61), more than two-thirds of the subjects (77%) were white and ranged in age from 23 to 63 years, with a mean age of 43.7 years. The majority of the analysis sample was female.
Results

Subject Characteristics
Health Effects
Blinded Analyses
Of the 29 subjects completing the interview in Trial 2001, 26 (90%) reported at least one health change. Overall, a total of 73 health changes were reported (Table 2 denotes those changes reported by at least two subjects), all but ten of which were considered positive. Among the positive changes noted, improved mood (n = 13), increase in activities (n = 7), improved thinking/cognition (n = 6), and increased energy (n = 5) were most frequently reported. Additionally, smaller themes in reported changes of improved emotions, feeling better, absence of suicidal ideation, improved anxiety, improved communication, increased interest, improved physical health, and positive thoughts were observed. Few themes were identified in the ten reported negative health changes. Two subjects noted a worsening in depressed mood, and one subject reported two instances of a slight headache.
Of the 61 subjects completing the interview in Trial 2002, 45 (74%) reported at least one health change since starting the study medication. A total of 174 health changes were reported by subjects and recorded by the interviewers ( Table 2 ). All reported health changes can be viewed in electronic supplementary material 1, and an additional 29 health changes were identified by the qualitative analysis during review of the transcripts. Because these additional 29 changes were not captured during the interview, the nature of the impact of the health change (i.e., positive, negative, or no impact) was not assessed by the subject. Of the 174 health changes recorded by the interviewers, 114 (66%) were noted to be positive. Among those positive changes, improved mood (n = 19), improved motivation (n = 13), improved socialization (n = 13), increased energy (n = 10), and improved concentration (n = 9) were most frequently reported. Additionally, improved sleep and decreased anxiety were also reported. Of the 174 health changes, 47 negative findings (27%) were reported. Among those, sleepiness/ feelings of being tired or exhausted (n = 6) were most often reported. An additional 13 health changes that subjects deemed to have no impact were reported.
When ranking the importance of health changes, most subjects in Trial 2001 reporting a positive health change indicated that the change was at least moderately important. Most subjects ranked the negative health changes they reported as slightly or moderately important (Table 3) . In Trial 2002, subjects deemed the majority of positive health changes and negative health changes to be either very or extremely important (Table 3) .
Unblinded Analyses
Following the blinded analysis, responses to reported health changes were further stratified by treatment group assignment. Notable changes reported by subjects receiving active treatment in Trial 2001 related to symptoms associated with depression (e.g., improved mood, increased energy, increased interest). Additionally, six subjects reported improved cognitive abilities following study therapy (e.g., more alert, cognitive clarity, more mentally capable). Clear themes were detected within the active treatment arms of Trial 2002, including changes of improved mood, increased energy, improved motivation, improved socialization, improved sleep, and improved concentration. Additionally, nine subjects reported improved concentration, clear thinking, or mental clarity. A small number of negative health changes were detected; however, only the health change of sleepiness emerged as a consistent theme that was reported within the placebo group. Table 4 provides a summary of the type of health change (i.e., positive or negative) by treatment group for both trials. Table 5 presents a summary of the identified health change themes found within the combined active treatment groups for Trial 2002.
Subjects' Willingness to Continue Study Medication and Comments About Treatment
Of 29 subjects in Trial 2001, 27 subjects (93%) reported at least "moderate" interest in continuing to take the study medication (Table 6 ). Overall, 23 subjects (79%) indicated that their interest in continuing the study medication was based on perceived drug efficacy. Of 61 subjects in Trial 2002, 50 subjects (82%) reported at least "a little" interest in continuing to take the study medication (Table 6 ). Of these 50 subjects, 42 (84%) expressed interest in continuing the study medication because of perceived drug efficacy. Subjects' comments about the study medication, including comments about their willingness to continue with treatment are included in electronic supplementary material 2.
Interview Quality
A quality review assessment was completed for Trial 2002. The majority of interviews conducted were of good to excellent quality. Overall, interviewers made good use of probes, restated health changes to subjects to ensure that the changes were being captured and recorded appropriately, and, in many cases, identified health changes that were reported outside of responses to Question 1 (please describe any health changes you noticed). During review of the transcripts, however, an additional 29 health changes were identified that were not previously reported by interviewers.
Discussion
A standardized exit interview provided insight into the patient-perceived treatment experience in early-phase studies 2001 and 2002 [7, 8] , thereby informing the development plan for esketamine. The interview was designed to detect both positive and negative signals of this investigational compound and to more fully describe the patientperceived treatment experience that may not have been captured by other COA measures or clinical indices alone. To avoid patient burden, the interview was brief and employed eight questions that included both closed and open-ended questions with standardized response probes. The sponsor trained site staff on both the conduct of the interview and data collection procedures and monitored the interviewers to optimize interview quality. Additionally, the use of audiorecordings and transcripts in Trial 2002 added to the depth and richness of the qualitative dataset based on the capture of 29 additional health changes that were reported during the course of the interview but not captured on the paper data collection worksheet. Prior to analysis of the interview data, audio-recorded interviews were reviewed by experienced qualitative researchers to assess interview quality. Quality indicators included the use of a standardized interview script, interview probes, and monitoring of the overall technique of the interviewer (for example, avoidance of bias/ leading questions, interviewer fatigue, and accuracy of the data collection worksheet). Importantly, nearly all interviews received a rating of "good" to "excellent" quality from the independent quality review team. Standardization and robust reported at least one health change. Importantly, most subjects rated the importance of these health changes to be at least of moderate importance, with the majority noting these changes were "very" to "extremely important" to study subjects. The majority of positive health changes (80% of overall positive changes in Trial 2001 and 89% in 2002) were described by participants receiving active therapy alone and the majority of negative health changes (57% in 2002) by patients who 
Health change pattern Subjects reporting health change pattern, n (%)
Two health changes Improved mood-increased energy/improved physical activity 8 (22.9) Improved mood-improved motivation 6 (17.1) Improved mood-improved socialization 6 (17.1) Decreased anxiety-improved mood 5 (14.3) Improved socialization-increased energy/improved physical activity 5 (14.3) Decreased anxiety-increased energy/improved physical activity 3 (8.6) Improved concentration-improved mood 3 (8.6) Improved concentration-improved motivation 3 (8.6) Improved concentration-improved socialization 3 (8.6) Improved concentration-increased energy/improved physical activity 3 (8.6) Improved concentration-increased interest 3 (8.6) Improved mood-improved sleep 3 (8.6) Improved mood-increased interest 3 (8.6) Improved motivation-improved socialization 3 (8.6) Improved motivation-increased energy/improved physical activity 3 (8.6) Improved sleep-increased energy/improved physical activity 3 (8.6) Increased energy/improved physical activity-increased interest 3 (8.6) Three health changes Decreased anxiety-improved mood-increased energy/improved physical activity 3 (8.6) Decreased anxiety-improved mood-improved motivation 2 (5.7) Decreased anxiety-improved mood-improved socialization 2 (5.7) Improved concentration-improved mood-improved motivation 2 (5.7) Improved concentration-improved mood-increased energy/improved physical activity 2 (5.7) Improved concentration-improved sleep-increased energy/improved physical activity 2 (5.7) Improved concentration-improved socialization-increased energy/improved physical activity 2 (5.7) Improved mood-improved motivation-increased energy/improved physical activity 2 (5.7) Improved mood-improved sleep-increased energy/improved physical activity 2 (5.7) Improved mood-improved socialization-increased energy/improved physical activity 2 (5.7) Improved mood-increased energy/improved physical activity-increased interest 2 (5.7) received only placebo (see Table 4 ), which illustrates the ability of the interview process to capture both positive and negative signals as well as the sensitivity to fully explore treatment effects. The use of PRO measures in clinical trials of depressive disorders has increased over time [11] . Despite the importance of these tools, selection of appropriate measures that have a demonstrated ability to evaluate treatment effects via assessment of concepts of interest that are relevant and important to patients in the target population continues to present challenges to both clinicians and investigators. The complex relationship between depression severity and patient reports of symptom burden, functioning and quality of life, and poor overall performance complicates the selection of highly sensitive measures that are able to demonstrate treatment benefit [12] . Unblinded analyses of the 2001 and 2002 study data described treatment benefits related not only to anticipated changes of improved mood but also potential cognitive benefits, mental alertness, improved sleep, and concentration. Data from these interviews were used to assist in phase III endpoint selection by carefully reviewing identified concepts from the health changes described by patients with established concepts assessed via COAs regularly employed in trials of depressive disorder, increasing the sensitivity via the selection of tools evaluating concepts that are meaningful to patients and eliminating irrelevant constructs or measures, thus reducing the "noise" in the data.
Results of these interviews were a component of the wider, robust clinical development process undertaken to map concepts of clinical importance that were also meaningful to patients to inform an overall endpoint strategy for later phase trials. Specifically, the health changes noted in these interviews were summarized and mapped to proposed COAs integrated into the esketamine phase III development program to ensure adequate capture of patient-perceived health effects. For example, changes specific to symptoms of depression, the ability to function and socialize, were reported by subjects during the interviews. These findings endorsed observations from other lines of research (internal data) that these outcomes are important to patients with depression and provided support that these concepts are important to assess when using PROs.
Limitations
For Trial 2001, because the available data consisted of the information recorded on the data collection worksheet only, interpretation of some verbatim terms (e.g., "quieter, drive faults, lack of feeling in body") was limited because the context could not be ascertained from a transcript of the interview. Additionally, no further details were available for some of the other more general themes (e.g., improved physical health, stomach disorder). Because there were no transcripts available, there was no ability to conduct a quality-control process or provide intermittent feedback to the site staff conducting the interviews.
For Trial 2002, the "cluster" patterns should be interpreted with caution, as the qualitative evaluation was limited by sample size and it is not known if additional factors including comorbidities, concomitant medication use, or other unknown factors may be contributing to these findings. While site staff were provided with training to facilitate interviewer neutrality and relevant feedback based on quality control (Trial 2002) , as opposed to use of external independent experienced interviewers, the familiarity of the site staff to patients may present a potential for response bias.
Conclusions
This patient-based evidence supported the design of phase III trials where function and associated disability and symptoms of depression were assessed using PROs and were integrated into pivotal trials as key secondary endpoints. Measurement of these important concepts from the patient perspective provided data intended to assist the interpretation of treatment effects observed in phase III trials. Therefore, patients were asked to respond to items that are meaningful and for which there was a rationale for relevance in the assessment of treatment effects both positive and negative in the target population.
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